SUBSCRIBE
SUBSCRIBE

AriBio USA, INC.

IN THE PRESS
Drug Development
AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)
April 28, 2024
 · 
3 min read
Drug Development
AriBio Licenses Exclusive Marketing Rights for AR1001 for Alzheimer’s Disease in China for $770 Million USD
March 24, 2024
 · 
2 min read
Drug Development
MHRA Issues Notice of Acceptance for POLARIS-AD, a Phase 3 Early Alzheimer’s Disease Trial Sponsored by AriBio Co., Ltd.
February 25, 2024
 · 
2 min read
Drug Development
AriBio Co., Ltd. Announces Global Expansion of POLARIS-AD, A Phase 3 Early Alzheimer’s Disease Registration Trial
November 14, 2023
 · 
3 min read
Business
AriBio Co., Ltd. and Fujirebio Diagnostics, Inc. Announce Strategic Partnership to Advance Biomarker Development for Alzheimer’s Disease and Neurodegeneration
March 8, 2023
 · 
3 min read
Drug Development
First Participants Enrolled in the AriBio USA Phase 3 Registration Trial to Evaluate AR1001 in Early Alzheimer’s Disease
January 5, 2023
 · 
2 min read
Drug Development
AriBio Co., Ltd. Announces Topline Results from Phase 2 Study of AR1001 in Mild to Moderate Alzheimer’s Patients
November 4, 2021
 · 
4 min read
Drug Development
AriBio Announces Completion of Enrollment in Phase 2 Alzheimer’s Study with AR1001
June 17, 2020
 · 
2 min read
Drug Development
AriBio Co., Ltd. Announces First Patient Dosing in Phase 2 Study of AR1001 for Alzheimer’s Disease
April 11, 2019
 · 
1 min read
Business
Vivione Biosciences Forms Strategic Alliance With AriBio
February 12, 2014
 · 
5 min read